| ［1］ |
郑民华, 马君俊.不断推进中国腹腔镜直肠癌手术规范化［ J/CD］.中华普外科手术学杂志（电子版）, 2023, 17（05）: 473-476.
|
| ［2］ |
杜晓辉, 晏阳.腹腔镜低位和超低位直肠癌术式选择与原则［ J/CD］.中华普外科手术学杂志（电子版）, 2023, 17（05）: 477-479
|
| ［3］ |
Blank CU, Rozeman EA, Fanchi LF, et al.Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma［ J］.Nat Med, 2018, 24(11): 1655-1661.
|
| ［4］ |
Forde PM, Chaft JE, Smith KN, et al.Neoadjuvant PD-1 Blockade in Resectable Lung Cancer［ J］.N Engl J Med, 2018, 378(21):1976-1986.
|
| ［5］ |
Chalabi M, Fanchi LF, Dijkstra KK, et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers［ J］.Nat Med, 2020,26(4): 566-576.
|
| ［6］ |
Le DT, Durham JN, Smith KN, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade［ J］.Science,2017, 357(6349): 409-413.
|
| ［7］ |
Jin Y, Jiang J, Mao W, et al.Treatment strategies and molecular mechanism of radiotherapy combined with immunotherapy in colorectal cancer［ J］.Cancer Lett, 2024, 591: 216858.
|
| ［8］ |
Wang Y,Shen L, Wan J, et al.Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer:A new era for anal preservation［ J］.Front Immunol, 2022, 13:1067036.
|
| ［9］ |
Bando H, Tsukada Y, Inamori K, et al.Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer［ J］.Clin Cancer Res, 2022,28(6): 1136-1146.
|
| ［10］ |
Yang Z, Gao J, Zheng J, et al.Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study［ J］.Signal Transduct Target Ther, 2024, 9(1): 56.
|
| ［11］ |
Lin ZY, Zhang P, Chi P, et al.Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial［ J］.Ann Oncol, 2024.
|
| ［12］ |
Wang YQ, Shen LJ, Wan JF, et al.Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre,randomized phase II trial (TORCH)［ J］.Zhonghua Wei Chang Wai Ke Za Zhi, 2023, 26(5): 448-458.
|
| ［13］ |
Rahma OE, Yothers G, Hong TS, et al.Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial［ J］.JAMA Oncol, 2021, 7(8): 1225-1230.
|
| ［14］ |
Li Y, Pan C, Gao Y, et al.Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer［ J］.JAMA Surg, 2024, 159(5): 529-537.
|
| ［15］ |
Xiao WW, Chen G, Gao YH, et al.Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial［J］.Cancer Cell, 2024,42(9):1570-1581.e4.
|
| ［16］ |
Zhou L, Yu G, Shen Y, et al.The clinical efficacy and safety of neoadjuvant chemoradiation therapy with immunotherapy for the organ preservation of ultra low rectal cancer: A single arm and open label exploratory study［ J］.Journal of Clinical Oncology,2022, 40(16_suppl): e15603-e.
|
| ［17］ |
George TJ, Yothers G, Rahma OE, et al.Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer(LARC)［ J］.Journal of Clinical Oncology, 2023, 41(4_suppl): 7.
|
| ［18］ |
Tsukada Y,Bando H,Inamori K,et al.Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer［ J］.Br J Cancer, 2024, 131(2): 283-289.
|
| ［19］ |
Lin Z, Zhai M, Zhang P, et al.Three-year survival data from a phase 2 trial of neoadjuvant short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer［ J］.Journal of Clinical Oncology, 2024, 42(16_suppl):e15611-e.
|
| ［20］ |
邱小原, 孙丽婷, 王晨童, 等.直肠癌新辅助免疫治疗相关不良反应分析：一项全国多中心回顾性研究［ J］.中国实用外科杂志, 2024, 44(07): 787-792.
|
| ［21］ |
Coutzac C, Adam J, Soularue E, et al.Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities［ J］.J Crohns Colitis, 2017,11(10): 1238-1246.
|
| ［22］ |
中国直肠癌新辅助治疗后等待观察数据库研究协作组, 中华医学会外科学分会结直肠外科学组, 中国医师协会结直肠肿瘤医师专业委员会, 等.直肠癌新辅助治疗后等待观察策略中国专家共识（2024版）［J］.中华胃肠外科杂志, 2024, (04):301-315.
|
| ［23］ |
Xie Y, Lin J, Zhang N, et al.Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors［ J］.J Natl Compr Canc Netw, 2023, 21(2): 133-142.e3.
|
| ［24］ |
Lin Z,Cai M, Zhang P, et al.Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer ［J］.J Immunother Cancer, 2022, 10(2): e003554corr1.
|
| ［25］ |
Yang Z, Ma J, Han J, et al.Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer［ J］.Med, 2024,5(10): 1293-1306.e4.
|
| ［26］ |
Hu H, Kang L, Zhang J, et al.Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repairdeficient or microsatellite instability-high, locally advanced,colorectal cancer (PICC): a single-centre, parallel-group, noncomparative, randomised, phase 2 trial［ J］.Lancet Gastroenterol Hepatol, 2022, 7(1): 38-48.
|
| ［27］ |
Yao H, Gao J, Yang Z, et al.Efficacy and safety of neoadjuvant chemoradiotherapy combined with tislelizumab and thymalfasin in the treatment of locally advanced lower rectal cancer［ J］.Journal of Clinical Oncology, 2024, 42(16_suppl): e15612-e.
|